Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Shionogi, StemRIM Extend Collaboration for “Regeneration-Inducing Medicine”
July 1, 2020
- Chugai Files Polatuzumab Vedotin for DLBCL in Japan
July 1, 2020
- Otsuka, Axcelead Link Up for Drug Discovery in CNS Field
July 1, 2020
- Nichi-Iko to Suspend Supply of Olmesartan OD Tab. 20 mg as COVID-19 Cripples API Procurement
July 1, 2020
- AnGes Launches Clinical Trial for Coronavirus DNA Vaccine
July 1, 2020
- Novo Japan Chief Sees 100 Billion Yen Target Achievable on Ozempic, Rybelsus
June 30, 2020
- Sanofi Launches Japan’s 1st Humalog Biosimilar
June 30, 2020
- EU Advisory Panel Snubs Daiichi Sankyo Cancer Med Pexidartinib
June 30, 2020
- Takeda to See US$200 Million Operating Loss Tied to Novartis' EU Xiidra Withdrawal
June 30, 2020
- Mitsubishi Tanabe Files Inebilizumab in Japan for NMOSD
June 29, 2020
- Pfizer Japan Boosting Biosimilar Sales Structure with Dedicated Unit, Ups Its Quality Pitch
June 29, 2020
- AstraZeneca in Talks with Daiichi Sankyo, Meiji Group on COVID-19 Vaccine Supplies in Japan
June 29, 2020
- Eisai’s Parkinson’s Med Equfina Gets South Korea Nod
June 26, 2020
- Sosei, AbbVie Link Arms for Inflammatory and Autoimmune Disease Drugs
June 26, 2020
- Carna Biosciences Takes Back Kinase Inhibitor from Canadian Licensee
June 26, 2020
- Japan Sales Rep Promotions in April Tumble 61% YOY: Intage
June 25, 2020
- Takeda’s CEO Pay Tops 2 Billion Yen in FY2019; Old Guard Pitch to Send in External Director Rejected
June 25, 2020
- Orphan Status Granted to Otsuka Gene Therapy, SanBio Cell Program
June 25, 2020
- 7 Authorized Generics in June Listing Target Combined 260 Billion Yen Market; Simultaneous Launches Catching On
June 24, 2020
- Rohto to Launch Stem Cell Clinical Trial for COVID-19 in August, Eyes Conditional OK
June 24, 2020
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…